Paris, France

David Klatzmann

USPTO Granted Patents = 33 

 

Average Co-Inventor Count = 2.7

ph-index = 9

Forward Citations = 380(Granted Patents)


Company Filing History:

goldMedal13 out of 316 
 
Assistance Publique-hopitaux De Paris
 patents
silverMedal9 out of 235 
 
Sorbonne Université
 patents
bronzeMedal6 out of 42 
 
Université Pierre Et Marie Curie (Paris Vi)
 patents
46 out of 1,743 
 
Institut National De La Sante Et De La Recherche Medicale
 patents
55 out of 155 
 
Université Pierre Et Marie Curie (Paris 6)
 patents
65 out of 67 
 
Université Pierre Et Marie Curie
 patents
73 out of 5,069 
 
Centre National De La Recherche Scientifique
 patents
83 out of 74 
 
Consejo Nacional De Investigaciones Cientificas Y Tecnicas (conicet)
 patents
92 out of 2 
 
L'universite Pierre Et Marie Curie
 patents
102 out of 3 
 
Universite De Reims Champagne-ardennes
 patents
112 out of 869 
 
Institut Pasteur
 patents
122 out of 4 
 
Iltoo Pharma
 patents
132 out of 3 
 
Universidad Catolica De Cordoba
 patents
141 out of 190 
 
Rhone-poulenc, Inc.
 patents
151 out of 31 
 
Genetic Systems Corporation
 patents
161 out of 20 
 
Variation Biotechnologies Inc.
 patents
171 out of 1 
 
Universidad Catolica De Corcoba (ucc)
 patent
181 out of 278 
 
Universitè De Montpellier
 patents
191 out of 3 
 
Universite Pierre Marie Curie
 patents
201 out of 1 
 
Inserm (Institut National De La Santé Et De La
 patent
211 out of 1 
 
Recherche Médicale)
 patent
221 out of 36 
 
Inserm (institut National De La Sante Et De La Recherche Medicale)
 patents
233 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1996-2025

Loading Chart...
Loading Chart...
33 patents (USPTO):Explore Patents

Title: David Klatzmann: Pioneering Immunologist with Numerous Patents

Introduction:

Throughout his illustrious career, David Klatzmann has been widely recognized for his exceptional contributions to the field of immunology. With a remarkable portfolio of 31 patents and a focus on novel therapies for autoimmune and inflammatory diseases, Klatzmann's groundbreaking work has had a transformative impact on medical research and treatment. Let us delve deeper into his latest patents, career highlights, and collaborations that have shaped the field of immunology.

Latest Patents:

Among Klatzmann's recent patents, two stand out as significant contributions to the field. The first patent covers the invention of genetically modified T lymphocytes, specifically regulatory T (Treg) cells or effector T cells (Teff), which stably express interleukin-2 (IL-2) or interleukin-15 (IL-15). This composition represents a promising avenue for immunotherapy research and drug development.

His second latest patent centers on the use of low dose interleukin-2 (IL-2) for treating autoimmune-related or inflammatory disorders. This invention aims to provide effective and targeted therapies for autoimmune and inflammatory diseases, with a particular focus on type I diabetes and other related conditions. Klatzmann's work in this area holds great promise for improving the lives of individuals suffering from these debilitating conditions.

Career Highlights:

David Klatzmann's remarkable career spans various prestigious institutions. He has worked at the Universite Pierre Et Marie Curie (Paris 6), where he made significant breakthroughs in immunology and contributed to the advancement of scientific knowledge. Additionally, Klatzmann has collaborated with the Assistance Publique—Hôpitaux De Paris, a leading healthcare provider in Paris, further enhancing the translation of his research into practical applications.

Collaborations:

During his career, Klatzmann has had the privilege of working alongside renowned scientists and researchers. Notably, he has collaborated closely with esteemed colleagues such as Jean-Loup Salzmann and Eliane Piaggio. These partnerships have fostered a vibrant scientific community dedicated to tackling the complexities of immunology and developing innovative solutions for challenging diseases.

Conclusion:

David Klatzmann's exceptional contributions to immunology, as evidenced by his numerous patents and groundbreaking research, have solidified his place as a leading figure in the field. His work on genetically modified T lymphocytes and the use of low dose interleukin-2 for autoimmune diseases showcases his commitment to improving medical treatments and finding novel therapeutic solutions. As the field of immunology continues to thrive, Klatzmann's work serves as an inspiration for future researchers and offers hope for those suffering from autoimmune and inflammatory disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…